CoChat

The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation

The DOI matches its Crossref record.

Abstract

Benzodiazepine discontinuation is characterized by a syndrome of increased activity and reduced seizure threshold that is similar to effects mediated by the glutamatergic system. To elucidate the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation, we administered lorazepam, the NMDA antagonist CPP, and the combination of these compounds either concomitantly or consecutively to mice via osmotic pumps and evaluated pentylenetetrazole-induced seizure threshold, open-field activity, and benzodiazepine receptor binding during and after chronic administration. Animals receiving lorazepam alone developed partial tolerance at 7 days and complete tolerance at 14 days to the anticonvulsant effects of lorazepam. This effect was partly attenuated by CPP coadministration with lorazepam. This combination produced only partial tolerance. A reduction in seizure threshold was observed 4 days after discontinuation of lorazepam alone. This effect was abolished by coadministration of CPP with lorazepam and by CPP administration during the withdrawal period. Benzodiazepine binding in most structures examined was significantly reduced at 14 days during chronic lorazepam administration (versus 1 day), and coadministration of CPP did not alter this decrement. After lorazepam discontinuation, binding was increased at 4 and 7 days versus chronically treated animals and versus vehicle within the cerebral cortex. This effect was abolished by coadministration of CPP as well as by CPP administration during the lorazepam withdrawal period. These data support the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation.

Overview

Integrity signals

Registry

Crossref · 10.1159/000139531

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 33

Metadata

Authors
Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G.
Affiliations
Tufts University (US)
Venue
Pharmacology
Publisher
S. Karger AG
Published
2008-06-10
Volume
55
Issue
5
Pages
217-227
ISSN
  • 0031-7012 (ISSN-L)
  • 1423-0313
OpenAlex
W2017337653
Cited by
33
References
0
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2013: 1 · 2012: 2
FWCI
0.43
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01mh047598-03)
  • National Institute of Mental Health (MH 34223, MH-47598)
  • National Institute on Drug Abuse (DA05258)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
benzodiazepine tolerance, benzodiazepine discontinuation, NMDA receptor antagonists, CPP, lorazepam, glutamatergic system, seizure threshold, benzodiazepine binding, benzodiazepine withdrawal, pentylenetetrazole-induced seizures, cerebral cortex
MeSH terms
Animals, Cerebral Cortex, Drug Interactions, Drug Tolerance, Hippocampus, Lorazepam, Male, Motor Activity, Pentylenetetrazole, Piperazines, Receptors, GABA-A, Seizures, Substance Withdrawal Syndrome, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. https://app.cochat.ai/papers/10.1159/000139531
The paper
Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G. (2008). The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. Pharmacology. https://doi.org/10.1159/000139531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.